Biosimilar natalizumab is aproved by FDA.
Vivacelle Bio, Inc.’s Post
More Relevant Posts
-
We, at VivacelleBio are proud and excited and looking forward to complete the study, so that there is a better option available for hypovolemia, especially relative hypovolemia in septic shock patients in very near future.
CEO & Director at Vivacelle Bio, Inc. I Life, Chemical & Pharma. Sciences COO, VP, Business Development, Head, Corporate & IP Strategy & Snr. Adviser, Operations, Pre-discovery, Preclinical & Clinical Stage Development.
https://lnkd.in/g3tbsgby We are elated to announce the initiation of a Phase 3 Trial for our Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock. CONGRATS to TEAM VIVACELLE BIO Cuthbert Simpkins,MD Krishna Talluri, MDMukesh Kumar, PhD, RAC 2Flo Ventures Propelevate Lacarya Scott, CFA
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock
prnewswire.com
To view or add a comment, sign in
-
📣 Vivacelle Bio, Inc. Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock "Septic shock results from whole body infection resulting in lower blood pressure and is associated with a third of all hospital deaths in the U.S., making it both the most significant cause of hospital-related mortality and the most expensive. Globally more deaths are caused from sepsis than cancer each year (11M vs. 9.6M) including 3.4M children." Learn more about our lead asset and its importance here: https://lnkd.in/gpcKi3uQ #HealthEquity #VivacelleBio
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock
prnewswire.com
To view or add a comment, sign in
-
Vivacelle Bio had a very successful clinical trial of its phospholipid nanoparticles in patients with severe septic shock who were not responding to standard of care. Vivacelle Bio company statement: The relatively unexplored region between life and death is the focus of our scientific journey and the source of our life saving discoveries. https://lnkd.in/ejD7aFtW
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
To view or add a comment, sign in
-
Vivacelle Bio had a very successful clinical trial of its phospholipid nanoparticles in patients with severe septic shock who were not responding to standard of care. Vivacelle Bio company statement: The relatively unexplored region between life and death is the focus of our scientific journey and the source of our life saving discoveries. https://lnkd.in/ejD7aFtW
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
To view or add a comment, sign in
-
Vivacelle Bio had a very successful clinical trial of our phospholipid nanoparticles in patients who had severe septic shock. he study was published in the Lancet's eClinicalmedicine. The company is moving on to phase III. https://lnkd.in/ejD7aFtW
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
To view or add a comment, sign in
-
https://lnkd.in/dWZmUakc We, the VivacelleBio team proud to present our Ph 2a study results published in The Lancet. #VBI-S #SepticShock #Hypotension #MAPimprovement
Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2a clinical pilot trial
thelancet.com
To view or add a comment, sign in
-
There we have it. Now we cannot easily say which countries drive on the wrong/right side of the road… Reasonable and enlightening explanation. #OldVSNotSoOld #LeftVSright
The History Behind Driving on the Left or Right Side of the Road
elaireinsurance.com
To view or add a comment, sign in
-
Is it really a name change ?! Change in strategy on the other hand is inevitable for any company as times are changing rapidly. If good things result from it, why not….
Why Novartis is changing the name of its research labs
https://www.statnews.com
To view or add a comment, sign in
349 followers